Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State

Abbye E. McEwen¹, Seth Cohen², Chloe Bryson-Cahn², Catherine Liu³, Steven A. Pergam³, John Lynch², Adrienne Schippers⁴, Kathy Strand⁴, Estella Whimbey², Nandita S Mani², Allison J. Zelikoff⁵, Vanessa A. Makarewicz⁵, Elizabeth R. Brown³, Shah A. Mohamed Bakhsh¹, Noah R. Baker¹, Jared Castor¹, Robert J. Livingston¹, Meei-Li Huang¹, Keith R. Jerome^{1,3}, Alexander L. Greninger^{1,3*}, Pavitra Roychoudhury^{1,3*#}

¹ Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA

² Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA

³ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

⁴ Department of Infection Prevention and Employee Health, University of Washington Medical Center, Seattle, WA, USA

⁵ Harborview Medical Center, University of Washington, Seattle, WA, USA

*co-senior authors

#Corresponding author

Pavitra Roychoudhury, proychou@uw.edu

1100 Fairview Ave N, E5-110, Seattle WA 98109-1024, USA

Phone: 206-616-4948

25

26 Keywords: SARS-CoV-2, vaccine breakthrough, variants of concern, sequencing

27

28 **Abstract**

29 Across 20 vaccine breakthrough cases detected at our institution, all 20 (100%) infections were
30 due to variants of concern (VOC) and had a median Ct of 20.2 (IQR=17.1-23.3). When compared
31 to 5174 contemporaneous samples sequenced in our laboratory, VOC were significantly
32 enriched among breakthrough infections ($p < .05$).

33

34

Main text

Vaccination against SARS-CoV-2 elicits an immune response capable of potentially neutralizing the virus. Multiple SARS-CoV-2 vaccines have been approved for use in humans through emergency use authorization or are in phase 3 clinical trials. Most of these vaccines use a recombinant spike protein derived from the first sequenced (Wuhan) strain from January 2020. The most widely used vaccines (mRNA-based mRNA-1273 and BNT162b2) have shown up to 95% efficacy at preventing clinical cases and up to 100% efficacy in preventing severe disease [1]. However, there is growing concern that emerging variants may escape vaccine-induced immunity and result in breakthrough infections in fully vaccinated individuals [2].

Since emerging in humans, SARS-CoV-2 is now defined by a variety of lineages harboring distinctive genetic changes in the spike protein. Variants of concern (VOCs) are those strains that show evidence of increased transmissibility, more severe disease, reduced neutralization by antibodies elicited by past infection or vaccination, reduced efficacy of treatments, or failures in diagnostic detection. As of May 20, 2021, there are currently 4 VOC identified by the US SARS-CoV-2 Interagency Group (P.1, B.1.351, B.1.427, and B.1.429) that show reduced neutralization by convalescent and post-vaccination sera [3].

Although *in vitro* studies have shown that some variants of concern are less effectively neutralized by sera from vaccinated individuals [4], the clinical implications for post-vaccination breakthrough infection remain largely unknown. In this study, we examined SARS-CoV-2 genomes isolated from individuals identified as vaccine breakthrough cases and compared them to the background of SARS-CoV-2 sequences from Washington over the same time interval.

Methods

This work was approved by the University of Washington (UW) Institutional Review Board. The UW Virology Lab (UWVL) routinely performs SARS-CoV-2 whole genome sequencing of specimens received for clinical testing. In this study, cases were defined as patients who were

fully vaccinated against SARS-CoV-2 (> two weeks post-2nd dose of Pfizer or Moderna vaccine) who subsequently tested positive by RT-PCR. The control group included samples collected in WA from the same time period as the case samples that were sequenced at UWVL. SARS-CoV-2 was detected by RT-PCR as previously described using either the emergency use-authorized UW CDC-based laboratory-developed test, Hologic Panther Fusion or Roche Cobas SARS-CoV-2 tests [5]. Sequencing was attempted on all specimens with Ct < 36 using a multiplexed amplicon sequencing panel from Swift Biosciences [6] or Illumina COVIDSeq (Illumina Inc, USA). Consensus sequences were assembled using a custom bioinformatics pipeline described previously (https://github.com/greninger-lab/covid_swift_pipeline, [6]). We excluded SARS-CoV-2 genome sequences that were incomplete (length < 29kbp) or of low quality (>10% Ns). SARS-CoV-2 lineages and clades were assigned using the PANGOLIN (Phylogenetic Assignment of Named Global Outbreak LINEages, <https://pangolin.cog-uk.io/>) and NextClade (<https://clades.nextstrain.org/>) tools. Amino acid changes were annotated according to NextClade. Analysis and calculations were performed in R. Significant differences in case distributions according to variants of concern were determined using Fisher's exact test.

Results

Beginning in February 2021, SARS-CoV-2 genome sequencing was requested at UW Medicine hospitals and partners as part of investigations into post-vaccine breakthrough infections. A total of 20 cases were sequenced in this study, including 13 females, 6 males, and 1 with unknown sex. Ages ranged from 26 to 65 years (median=43, IQR=28-58) (Supplementary Table 1), and Ct values ranged from 16.00 to 35.86 (median=20.2, IQR=17.1-23.3). These specimens were collected between February 23 and April 27, 2021. The control group consisted of genomes sequenced by UWVL (n=5174) during the same period as the vaccine breakthrough cohort (Supplementary Table 1).

All 20 of 20 vaccine breakthrough cases were classified as variants of concern: 8 (40%) B.1.1.7, 1 (5%) B.1.351, 2 (10%) B.1.427, 8 (40%) B.1.429, and 1 (5%) P.1 (Figure 1A, Supplementary Table 2). In contrast, during the same time interval, 68% of WA cases

sequenced at UWVL represented VOC with 31% B.1.1.7, 1% B.1.351, 3% B.1.427, 27% were B.1.429, and 7% were P.1 (Figure 1B). Overall, variants of concern were proportionally over-represented in breakthrough cases, with the frequency of all VOCs in breakthrough increased 1.47-fold compared to the control group (95% CI [1.45, 1.50], $p=0.001$). Variants B.1.427, B.1.429, and B.1.1.7 were 3.38-fold (95% CI [0.90, 12.71], $p=0.119$), 1.51-fold (95% CI [0.88, 2.59], $p=0.203$), and 1.29-fold (95% CI [0.75, 2.20], $p=0.468$) more common in breakthrough cases compared to controls (Supplementary Figure 1, Supplementary Table 2). The overall distribution of variants was significantly different between breakthrough and control groups ($p=0.001$, Fisher's Exact test, Supplementary Table 2). Variants that have been reported to be less effectively neutralized by antibodies from post-vaccinated individuals (P.1, B.1.351, B.1.427, and B.1.429) were identified in 60% of breakthrough cases and 36.7% of control cases, a 1.63-fold change (95% CI [1.14, 2.34], $p=0.037$).

We compared the occurrence of individual mutations in spike in the breakthrough vs. control groups. A single mutation, W258L, was 15.22-fold enriched in breakthrough cases, 95% CI [3.91, 59.10], $p=0.008$ (Fig. 1D), but was present in only 2 cases. No other mutations showed significant enrichment in the breakthrough group.

Clinical data, including comorbidities and vaccination type and dates ($n=19$), were available for a subset of subjects (Supplementary Table 3). All patients received mRNA-based vaccines (14 BNT162b2, 5 mRNA-1273); 15 out of 18 reported symptoms, none required hospitalization. Specimens were collected at an average of 67.7 days after vaccination (range=39-112, $sd=18.1$).

Discussion

In this study, SARS-CoV-2 variants of concern were found to be overrepresented in vaccine breakthrough cases when compared to cases circulating in the general population of Washington State over the same time interval. Although no single VOC was significantly enriched in the breakthrough cases, subgroup analysis revealed that variants that have shown reduced antibody neutralization *in vitro* (B.1.351, B.1.427, B.1.429, and P1) were

overrepresented compared to the B.1.1.7 VOC lineage which is not associated with reduced neutralization. The 20 vaccine breakthrough cases described here also had a substantially stronger viral load than 22 breakthrough cases among Chicago nursing facility staff and residents recently reported by the CDC [7].

The B.1.427/B.1.429 variants were first identified in Los Angeles County, California in July of 2020 [8] and quickly became the dominant form of the virus circulating in that state. These variants were first seen in Washington State in December 2020 and comprised 30% of cases during the study period. The B.1.427/B.1.429 variants are characterized by key spike protein changes, with L452R in receptor binding domain and S13C and W152C in the N-terminal domain (NTD). Recent studies suggest that neutralizing antibody titers from plasma collected from vaccinated or convalescent individuals were reduced 2-7 fold against B.1.427/B.1.429 variant relative to wildtype [8,9]. Similarly, P.1 variant identified in Brazil and B.1.351 variant identified in South Africa also show reduced antibody neutralization efficiency, 4-5 and 5-40 fold, respectively [10,11]. Both P.1 and B.1.351 were uncommon in the control group, with P.1 comprising 6% of cases and B.1.351 less than 1% of cases. In contrast, the B.1.1.7 variant, first identified in the United Kingdom and known to increase infectivity by approximately 50%, is neutralized as efficiently as wild type or only minimally decreased in most studies [11–13]. B.1.1.7 was the major variant circulating in our area during the study period. While it is noted that the introduction of E484K into the B.1.1.7 background has been shown to introduce reduced neutralization efficiency [14], this mutation was not present in any of our breakthrough B.1.1.7 cases, so we considered this strain as having similar neutralization efficiency as wild-type. These data therefore suggest that *in vitro* neutralization assays may predict variants more likely to escape antibodies from vaccinated individuals.

Most mutations thought to lead to antibody neutralization resistance occur in the receptor binding domain of the spike protein [15]. Of note, 2 of 2 B.1.427 cases identified in the breakthrough group contained a spike mutation W258L outside of the receptor binding domain, compared to 50 of 208 (24.03%) in the control group. W258L resides in the so called “NTD-antigen supersite”. While antibodies that bind the receptor binding domain may target different epitopes, a single site of vulnerability to antibody neutralization exists in the NTD [16].

The impact of NTD alterations in antibody neutralization efficiency is largely unstudied. Our data suggest that *in vitro* studies of antibody neutralization residence should include NTD alterations such as W258L.

This study is limited by the small number of subjects in the vaccine breakthrough group, and we cannot exclude the presence of additional breakthrough cases in the control groups due to a lack of clinical data. Moreover, our breakthrough cohort was mostly composed of healthcare workers who were identified by infection control or employee health. In contrast, sequences from UWVL were sampled from across the state and include samples from various testing sites including hospitals, outpatient clinics, and community testing sites.

All 20 breakthrough cases in this study were assigned a lineage without conflicts. This contrasts with a recent study which demonstrated a novel variant in a post-vaccination individual that fell between clades 20B and 20C, raising concern that viral evolution may drive neutralization antibody resistance [2]. Continued surveillance of post-vaccine breakthrough cases may help target variants of concern for inclusion in new or booster SARS-CoV-2 vaccines.

Acknowledgements

Computational analyses were made possible by Scientific Computing Infrastructure at Fred Hutch and UW Laboratory Medicine IT cloud infrastructure.

Funding

This work is supported by the National Institutes of Health [ORIP grant S10OD028685 to Scientific Computing at Fred Hutch, and UW-Fred Hutch CFAR AI027757 to P.R.].

Conflicts of Interest

A.L.G. reports contract testing from Abbott Laboratories and research support from Gilead and Merck, outside of the described work.

References

1. Funk CD, Laferrière C, Ardakani A. Target product profile analysis of COVID-19 vaccines in Phase III clinical trials and beyond: An early 2021 perspective. *Viruses* **2021**; 13:418.
2. Hacisuleyman E, Hale C, Saito Y, et al. Vaccine breakthrough infections with SARS-CoV-2 variants. *N Engl J Med* **2021**; Available at: <http://dx.doi.org/10.1056/NEJMoa2105000>.
3. CDC. SARS-CoV-2 Variant Classifications and Definitions. 2021. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html>. Accessed 19 May 2021.
4. Garcia-Beltran WF, Lam EC, St Denis K, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. *Cell* **2021**; 184:2523.
5. Nalla AK, Casto AM, Huang M-LW, et al. Comparative Performance of SARS-CoV-2 Detection Assays Using Seven Different Primer-Probe Sets and One Assay Kit. *J Clin Microbiol* **2020**; 58. Available at: <http://dx.doi.org/10.1128/JCM.00557-20>.
6. Addetia A, Lin MJ, Peddu V, Roychoudhury P, Jerome KR, Greninger AL. Sensitive recovery of complete SARS-CoV-2 genomes from clinical samples using Swift Biosciences' SARS-CoV-2 multiplex amplicon sequencing panel. *J Clin Microbiol* **2020**; Available at: <http://dx.doi.org/10.1128/JCM.02226-20>.
7. Teran RA, Walblay KA, Shane EL, et al. Postvaccination SARS-CoV-2 infections among skilled nursing facility residents and staff members - Chicago, Illinois, December 2020-march 2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70:632–638.

8. Deng X, Garcia-Knight MA, Khalid MM, et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. *Cell* **2021**; Available at: <http://dx.doi.org/10.1016/j.cell.2021.04.025>.
9. Shen X, Tang H, Pajon R, et al. Neutralization of SARS-CoV-2 variants B.1.429 and B.1.351. *N Engl J Med* **2021**; Available at: <http://dx.doi.org/10.1056/NEJMc2103740>.
10. Wang P, Casner RG, Nair MS, et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. *Cell Host Microbe* **2021**; Available at: <http://dx.doi.org/10.1016/j.chom.2021.04.007>.
11. Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. *Nature* **2021**; 593:130–135.
12. Shen X, Tang H, McDanal C, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. *Cell Host Microbe* **2021**; 29:529-539.e3.
13. Edara VV, Floyd K, Lai L, et al. Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant. *medRxiv* **2021**; Available at: <http://dx.doi.org/10.1101/2021.02.02.21250799>.
14. Collier DA, De Marco A, Ferreira IATM, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. *Nature* **2021**; 593:136–141.
15. Focosi D, Maggi F. Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines. *Rev Med Virol* **2021**; Available at: <http://dx.doi.org/10.1002/rmv.2231>.
16. Cerutti G, Guo Y, Zhou T, et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. *Cell Host Microbe* **2021**; Available at: <http://dx.doi.org/10.1016/j.chom.2021.03.005>.

Figure 1: Variants of concern are overrepresented in vaccine breakthrough SARS-CoV-2

genomes A) Cumulative number of breakthrough cases and their Pangolin lineages. B)

Proportions of lineages for UWVL sequences collected during the same time period. Relative

risk of vaccine escape for each VOC (C) and spike amino acid change (D). Error bars represent

95% confidence intervals. * $p < 0.05$, ** $p < 0.01$ (Fisher's Exact Test). VOC: variant of concern

(total), VOC-WT: variant of concern without reduced neutralization, VOC-R: variant of concern

with reduced neutralization

Supplementary Figure 1. Heat map showing relative frequencies of variants of concern breakthrough vs. control cases.

231 **Supplementary Table 1: Study groups**

	Vaccine Breakthrough (n=20)	UWVL (n=5174)
Age (years)		
Range	26 - 65	0 - 98
Median	43	30
Mean	43.80	32.572
SD	11.61	16.582
IQR	29.75	14.000
Q1	34.00	21.00
Q2	43.00	30.00
Q3	48.00	44.00
Q4	65.00	98.00
Sex		
Female	13 (65.00%)	2439 (47.14%)
Male	6 (30.00%)	2592 (50.10%)
Unknown	1 (5.00%)	143 (2.76%)
Collection date		
Range	2/23/21 - 4/27/21	2/23/21 - 4/27/21
Median	3/29/2021	4/1/2021
Mean	3/29/2021	3/28/2021
IQR	26.50	24.00
Q1	3/17/2021	3/17/2021
Q2	3/29/2021	4/1/2021
Q3	4/13/2021	4/10/2021
Q4	4/27/2021	4/20/2021
Ct value		
Range	16.00 - 35.86	
Median	20.16	
Mean	21.59	
SD	5.32	
IQR	6.19	
Q1	17.82	
Q2	20.16	
Q3	24.00	
Q4	35.86	

232 SD = standard deviation, IQR = interquartile range, Q1= first quartile, Q2 = second quartile, Q3 = third quartile, Q4
233 = fourth quartile, Ct = PCR cycle threshold

234

235 **Supplementary Table 2: Variants of concern in case vs. control groups**

Vaccine Breakthrough (n=20)			UWVL (n=5174)				
N	20	%	N	%	Fold Increase	95% CI	P*
B.1.1.7	8	40.00%	1609	31.10%	1.29	[0.75, 2.20]	0.001
B.1.351	1	5.00%	37	0.72%	6.99	[1.01, 48.52]	
B.1.427	2	10.00%	153	2.96%	3.38	[0.90, 12.71]	
B.1.429	8	40.00%	1372	26.52%	1.51	[0.88, 2.59]	
P.1	1	5.00%	337	6.51%	0.77	[0.11, 5.20]	
Non-VOC	0	0.00%	1666	32.20%	--	--	--
Total-VOC	20	100.00%	3508	67.80%	1.47	[1.45, 1.50]	0.001
VOC-reduced affinity	12	60.00%	1899	36.70%	1.63	[1.140, 2.34]	0.037
VOC-not reduced affinity	8	40.00%	1609	31.10%	1.29	[0.750, 2.20]	0.468

236 *Fisher's Exact Test, VOC = variant of concern

7 **Supplementary Table 3: Breakthrough Cases**

Patient	Age range	Sex	Comorbidities	Symptomatic	Vaccine Type	Last Vaccine to Collection Date (Days)	Ct	NextClade Lineage	PANGO Lineage	Spike Amino Changes
P1	40-44	M	Hypertension, non-alcoholic steatohepatitis, hyperlipidemia, obstructive sleep apnea	YES	Pfizer	43	23.40	20C	B.1.427	S13I, W258L, L452R, D614G, C1236F
P2	30-34	F	Unknown	NO	Pfizer	39	20.69	20J/501Y.V3	P.1	L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F
P3	60-64	F	Diabetes (type II), non-alcoholic steatohepatitis, obstructive sleep apnea	Unknown	Unknown	70	35.86	20C	B.1.429	S13I, W152C, L452R, D614G
P4	26-29	F	Unknown	YES	Pfizer	54	17.56	20C	B.1.427	S13I, W152C, W258L, L452R, D614G
P5	60-64	F	Unknown	YES	Pfizer	66	19.61	20C	B.1.429	S13I, W152C, L452R, D614G, L141-, G142-, V143-
P6	35-39	F	None	YES	Pfizer	47	20.80	20C	B.1.429	S13I, W152C, L452R, D614G
P7	55-59	F	Hypothyroid, mild asthma	YES	Pfizer	66	26.40	20C	B.1.429	S13I, W152C, L452R, D614G
P8	40-44	M	Unknown	YES	Pfizer	55	24.00	20C	B.1.429	S13I, W152C, L452R, D614G
P9	40-44	F	Unknown	YES	Pfizer	77	16.40	20C	B.1.429	W152C, L452R, D614G
P10	50-54	F	None	YES	Pfizer	58	21.20	20I/501Y.V1	B.1.1.7	N501Y, A570D, D614G, P681H, T716I, S982A, D1118H, K1191N, H69-, V70-, Y144-
P11	65-69	F	None	YES	Moderna	44	19.62	20H/501Y.V2	B.1.351	D80A, D215G, L242H, K417N, D614G, A701V, A243-, L244-, H245-
P12	25-29	U	Unknown	YES	Pfizer	80	24.10	20C	B.1.429	S13I, W152C, L452R, D614G
P13	30-34	M	Unknown	NO	Moderna	70	18.90	20I/501Y.V1	B.1.1.7	S:D178H, S:N501Y, S:A570D, S:D614G, S:P681H, S:T716I, S:S982A, S:D1118H, S:H69-, S:V70-
P14	30-34	M	Unknown	YES	Moderna	73	17.90	20I/501Y.V1	B.1.1.7	S:D178H, S:N501Y, S:A570D, S:D614G, S:P681H, S:T716I, S:S982A, S:D1118H, S:H69-, S:V70-
P15	45-49	M	None	YES	Pfizer	77	17.45	20I/501Y.V1	B.1.1.7	S:N501Y, S:A570D, S:D614G, S:P681H, S:T716I, S:S982A, S:D1118H, S:H69-,

										S:V70-, S:Y144-
P16	45-49	F	Unknown	YES	Moderna	67	18.88	20I/501Y.V1	B.1.1.7	S:D178H, S:N501Y, S:A570D, S:D614G, S:P681H, S:T716I, S:S982A, S:D1118H, S:H69-, S:V70-
P17	40-44	M	Unknown	YES	Pfizer	96	16.10	20I/501Y.V1	B.1.1.7	S:N501Y, S:A570D, S:D614G, S:P681H, S:T716I, S:S982A, S:D1118H, S:H69-, S:V70-
P18	45-49	F	Unknown	NO	Pfizer	80	16.00	20I/501Y.V1	B.1.1.7	S:D178H, S:N501Y, S:A570D, S:D614G, S:P681H, S:T716I, S:S982A, S:D1118H, S:H69-, S:V70-
P19	45-49	F	Unknown	YES	Moderna	72	24.00	20C	B.1.429	S:S13I, S:P26S, S:W152C, S:L452R, S:D614G
P20	30-34	F	None	Unknown	Pfizer	112	33.00	20I/501Y.V1	B.1.1.7	S:S98F, S:D138H, S:A344V, S:N501Y, S:A570D, S:D614G, S:P681H, S:T716I, S:S982A, S:D1118H, S:H69-, S:V70-, S:Y144-

F = female, M = male, U = unknown sex, Ct = PCR cycle threshold

8
9
0